Allos Therapeutics Announces Pricing of Public Offering of Common Stock
07 Octobre 2009 - 12:14PM
Business Wire
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced the
pricing of an underwritten public offering of 14,000,000 primary
shares of its common stock at a public offering price of $7.10 per
share. The gross proceeds from the sale of the shares, before
underwriting discounts and commissions and other offering expenses,
are expected to be approximately $99.4 million. The offering is
expected to close on or about October 13, 2009, subject to
customary closing conditions. Allos has also granted the
underwriters a 30-day option to purchase up to an aggregate of
2,100,000 additional shares of common stock to cover
over-allotments, if any. All of the shares in the offering are
being sold by Allos.
Allos currently anticipates using the net proceeds of the
offering primarily for activities relating to the commercialization
of FOLOTYN™ (pralatrexate injection), preclinical research and
clinical development of FOLOTYN, and for general corporate
purposes.
J.P. Morgan Securities Inc. and Citigroup Global Markets Inc.
are acting as joint book-running managers of the offering. Leerink
Swann LLC is acting as co-lead manager of the offering. JMP
Securities LLC, Needham & Company, LLC, and RBC Capital
Markets are acting as co-managers of the offering. A copy of the
final prospectus supplement and accompanying prospectus relating to
the offering, when available, may be obtained by contacting J.P.
Morgan Securities Inc., Attention: Prospectus Department, 4 Chase
Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718)
242-8002 or Citigroup Global Markets Inc., Prospectus Department,
Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY
11220, (800) 831-9146.
A registration statement relating to these shares was declared
effective by the Securities and Exchange Commission on August 28,
2009. Any offer or sale will be made only by means of a written
prospectus supplement forming part of the effective registration
statement. This press release does not and shall not constitute an
offer to sell or the solicitation of an offer to buy Allos’ common
stock, nor shall there be any sale of the common stock in any state
or jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any state.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the Company’s expectations
regarding completion, timing and size of the proposed financing and
other statements which are other than statements of historical
facts. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "expects,"
"intends," "plans," anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar
terminology or the negative of these terms, but their absence does
not mean that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others: the risk that the financing may be delayed or may not
occur due to market or other conditions and the satisfaction of
customary closing conditions related to the proposed public
offering. Additional information concerning these and other factors
that may cause actual results to differ materially from those
anticipated in the forward-looking statements is contained in the
"Risk Factors" section of the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2009, and in the Company's
other periodic reports and filings with the Securities and Exchange
Commission and the prospectus supplement related to the offering.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Note: Allos Therapeutics, Inc., the Allos Therapeutics, Inc.
logo, FOLOTYN, the FOLOTYN logo and all other Allos names are
trademarks of Allos Therapeutics, Inc. in the United States and in
other selected countries.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024